Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$13.79M |
$1.04
-3.24%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$13.78M |
$0.47
|
|
BLRX
BioLineRx Ltd.
BioLineRx's lead oncology asset motixafortide (APHEXDA) places the company squarely in oncology with an approved stem cell mobilization therapy and ongoing cancer indications development.
|
$13.65M |
$2.91
+1.04%
|
|
ACUT
Accustem Sciences Inc.
Tests and technologies are oncology-focused biomarker diagnostics, placing ACUT in the oncology diagnostics space.
|
$13.61M |
$0.60
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$13.60M |
$0.06
|
|
THAR
Tharimmune, Inc.
THAR directly develops monoclonal antibody therapeutics (e.g., TH023 and IO assets HS1940/HS3215), fitting Monoclonal Antibody Therapeutics.
|
$13.53M |
$2.94
-0.68%
|
|
SNSE
Sensei Biotherapeutics, Inc.
Sensei's lead asset targets oncology/cancer indications, fitting the Biotech - Oncology category.
|
$13.17M |
$11.11
-4.31%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$12.99M |
$1.71
-1.72%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$12.44M |
$0.99
+4.22%
|
|
TRIB
Trinity Biotech plc
Includes companion diagnostics/biomarker-guided tests as part of its oncology-focused diagnostic portfolio.
|
$12.36M |
$0.69
-3.17%
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$12.30M |
$0.12
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$12.21M |
$6.40
-8.31%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$12.20M |
$0.31
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$12.17M |
$1.05
+0.96%
|
|
INAB
IN8bio, Inc.
INAB's core products are gamma-delta T cell therapies (INB-100, INB-200) and preclinical programs, a direct cell therapy offering.
|
$11.76M |
$2.58
+10.99%
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$11.46M |
$3.62
-0.82%
|
|
COCP
Cocrystal Pharma, Inc.
Cocrystal Pharma is actively developing antiviral small-molecule therapeutics (CC-42344, CDI-988, CC-31244) for influenza, norovirus/coronavirus, and HCV.
|
$11.39M |
$1.11
+0.45%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$11.00M |
$0.94
+1.08%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$10.57M |
$10.82
+1.55%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$10.36M |
$1.31
-0.76%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$10.27M |
$1.45
+2.11%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$9.99M |
$0.36
-1.98%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$9.82M |
$1.05
-15.32%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$9.59M |
$2.67
+5.53%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$9.34M |
$0.99
+1.44%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$9.28M |
$1.21
+2.12%
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$9.17M |
$1.15
|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$9.15M |
$1.05
+0.48%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$9.10M |
$4.16
+0.73%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$9.08M |
$1.22
+2.97%
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
XAIR
Beyond Air, Inc.
UNO program for solid tumors places Beyond Air in oncology-focused biotech pipelines.
|
$8.88M |
$1.72
-0.29%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$8.85M |
$1.96
+1.55%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$8.55M |
$0.52
-0.54%
|
Showing page 22 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
